and by the Belgian Inflammatory Bowel Disease Research and Development Grant 2023. JS and TV are supported by a senior ...

The biomarker assay can be used potentially to enrich clinical trials and monitor patients' disease activity and treatment response.

A randomized controlled trial finds no clear benefit of adding bezlotoxumab to FMT in patients with IBD and recurrent C difficile infection.

Aeglea Biotherapeutics Inc. ( (SYRE) ) has released its Q3 earnings. Here is a breakdown of the information Aeglea Biotherapeutics Inc.

Alcohol can worsen Crohn’s disease symptoms, but the impact varies from person to person. It may depend on what and how much ...

Researchers used pharmacovigilance data to examine the onset of gastrointestinal adverse events associated with the use of biologic therapies for psoriasis.

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the treatment process.

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious ...

Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients ...

Ulcerative colitis (UC) is a chronic gut inflammatory condition affecting the colon in humans. This study uses human samples as well as a mouse model of colitis induced by a chemical, DSS, to ...